Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBM-BMX in Advanced Solid Tumors
NCT03808870Phase 1Completed
- Sponsor
- NatureWise Biotech & Medicals
- Start
- Dec 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of NBM-BMX in solid tumor and glioblastoma (GBM) (2 arms), sponsored by NatureWise Biotech & Medicals. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Started Dec 2018; status: completed.
02
Drugs
NBM-BMX
03
Conditions
solid tumorglioblastoma (GBM)
Beyond the preview
Go deeper on NCT03808870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03808870.